ECSP067062A - Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso - Google Patents

Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso

Info

Publication number
ECSP067062A
ECSP067062A EC2006007062A ECSP067062A ECSP067062A EC SP067062 A ECSP067062 A EC SP067062A EC 2006007062 A EC2006007062 A EC 2006007062A EC SP067062 A ECSP067062 A EC SP067062A EC SP067062 A ECSP067062 A EC SP067062A
Authority
EC
Ecuador
Prior art keywords
compounds
compositions containing
use procedures
pirazol derivatives
pirazol
Prior art date
Application number
EC2006007062A
Other languages
English (en)
Inventor
Rui Liang
Emma R Parmee
Yusheng Xiong
Jian Guo
Linda Brockunier
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of ECSP067062A publication Critical patent/ECSP067062A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se revelan pirazoles que tienen un grupo naftilo unido. Los compuestos son útiles para tratar la diabetes de tipo 2 y dolencias relacionadas. También se incluyen composiciones farmacéuticas y procedimientos de tratamiento.
EC2006007062A 2004-06-04 2006-12-04 Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso ECSP067062A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US57711604P 2004-06-04 2004-06-04

Publications (1)

Publication Number Publication Date
ECSP067062A true ECSP067062A (es) 2007-01-26

Family

ID=35335786

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2006007062A ECSP067062A (es) 2004-06-04 2006-12-04 Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso

Country Status (34)

Country Link
US (2) US7598285B2 (es)
EP (1) EP1756064B1 (es)
JP (2) JP4108739B2 (es)
CN (1) CN1964947A (es)
AR (2) AR049291A1 (es)
AT (1) ATE395338T1 (es)
AU (2) AU2005252183B2 (es)
BR (1) BRPI0511703B8 (es)
CA (1) CA2566945C (es)
CR (1) CR8766A (es)
CY (1) CY1108544T1 (es)
DE (1) DE602005006806D1 (es)
DK (1) DK1756064T3 (es)
EA (1) EA012431B1 (es)
EC (1) ECSP067062A (es)
ES (1) ES2306165T3 (es)
GE (1) GEP20094605B (es)
HR (1) HRP20080311T3 (es)
IL (1) IL179754A (es)
MA (1) MA28673B1 (es)
MX (1) MXPA06014084A (es)
MY (1) MY143599A (es)
NI (1) NI200600290A (es)
NO (1) NO339149B1 (es)
NZ (1) NZ551405A (es)
PE (1) PE20060427A1 (es)
PL (1) PL1756064T3 (es)
PT (1) PT1756064E (es)
SI (1) SI1756064T1 (es)
TN (1) TNSN06397A1 (es)
TW (1) TWI293952B (es)
UA (1) UA85884C2 (es)
WO (1) WO2005121097A2 (es)
ZA (1) ZA200609489B (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004210127B2 (en) 2003-01-27 2009-10-01 Merck Sharp & Dohme Corp. Substituted pyrazoles, compositions containing such compounds and methods of use
NZ551405A (en) 2004-06-04 2009-06-26 Merck & Co Inc Pyrazole derivatives, compositions containing such compounds and methods of use
WO2006014618A2 (en) * 2004-07-22 2006-02-09 Merck & Co., Inc. Substituted pyrazoles, compositions containing such compounds and methods of use
CN101300232A (zh) * 2005-07-26 2008-11-05 默克公司 合成取代的吡唑的方法
AR056574A1 (es) * 2005-10-19 2007-10-10 Merck & Co Inc Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso
US20100099712A1 (en) * 2007-01-17 2010-04-22 Laboratorios Del Dr. Esteve, S.A. Substituted pyrazoline compounds with acat inhibition activity
KR20200123866A (ko) 2007-02-09 2020-10-30 메타베이시스 테라퓨틱스, 인크. 글루카곤 수용체의 길항제
WO2009005675A1 (en) * 2007-06-28 2009-01-08 Abbott Laboratories Novel triazolopyridazines
US8232413B2 (en) * 2007-09-12 2012-07-31 Merck Sharp & Dohme Corp. Process for the production of a crystalline glucagon receptor antagonist compound
BRPI0912245A2 (pt) 2008-03-05 2019-09-24 Takeda Pharmaceuticals Co composto, prodroga, medicamento, métodos de suprimir produção de açúcar em um mamífero e para a profilaxia ou o tratamento de diabetes em um mamífero, e, uso do composto
CN102083467B (zh) 2008-03-11 2013-12-25 Aska制药株式会社 固体分散体及其药物组合物、以及它们的制备方法
WO2009140342A1 (en) 2008-05-16 2009-11-19 Schering Corporation Glucagon receptor antagonists, compositions, and methods for their use
PT2799428T (pt) 2008-08-13 2017-02-17 Metabasis Therapeutics Inc Antagonistas de glicagina
RU2008135294A (ru) * 2008-08-29 2010-03-10 Дик Корпорейшн (Jp) Нафталиновые производные
EP2346830B1 (en) * 2008-09-15 2015-05-13 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
JP2012504630A (ja) * 2008-10-03 2012-02-23 シェーリング コーポレイション グルカゴン受容体アンタゴニストとしてのスピロイミダゾロン誘導体
US8324384B2 (en) 2009-02-12 2012-12-04 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
US8318667B2 (en) 2009-02-25 2012-11-27 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
WO2010144664A1 (en) * 2009-06-12 2010-12-16 Schering Corporation Thiophenes as glucagon receptor antagonists, compositions, and methods for their use
US8735604B2 (en) 2009-09-22 2014-05-27 Merck Sharp & Dohme Corp. Pyrrolidines as glucagon receptor antagonists, compositions, and methods for their use
NZ611529A (en) 2010-12-23 2015-06-26 Pfizer Glucagon receptor modulators
WO2012107850A1 (en) 2011-02-08 2012-08-16 Pfizer Inc. Glucagon receptor modulator
US8927577B2 (en) 2011-07-22 2015-01-06 Pfizer Inc. Quinolinyl glucagon receptor modulators
TW201427658A (zh) 2012-12-10 2014-07-16 Merck Sharp & Dohme 藉由投予升糖素受體拮抗劑及膽固醇吸收抑制劑治療糖尿病之方法
EP3065736B1 (en) 2013-11-04 2018-11-14 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions thereof, and methods of use
CN103933032B (zh) * 2013-12-30 2019-08-23 北京赛林泰医药技术有限公司 作为抗癌药物的吡唑类衍生物的使用方法和用途
WO2015191900A1 (en) 2014-06-12 2015-12-17 Ligand Pharmaceuticals, Inc. Glucagon antagonists
NZ750953A (en) 2016-08-30 2026-02-27 Regeneron Pharma Methods of treating severe insulin resistance by interfering with glucagon receptor signaling
TWI763705B (zh) * 2016-09-06 2022-05-11 比利時商健生藥品公司 可作為升糖素受體拮抗劑之吲哚衍生物
US20190248888A1 (en) 2016-10-20 2019-08-15 Regeneron Pharmaceuticals, Inc. Methods of lowering blood glucose levels
CA3071387A1 (en) 2017-08-22 2019-02-28 Regeneron Pharmaceuticals, Inc. Methods of treating urea cycle disorders by interfering with glucagon receptor signaling
WO2019160940A1 (en) 2018-02-13 2019-08-22 Ligand Pharmaceuticals Incorporated Glucagon receptor antagonists

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9303993D0 (en) 1993-02-26 1993-04-14 Fujisawa Pharmaceutical Co New heterocyclic derivatives
AU702887B2 (en) 1995-10-31 1999-03-11 Merck & Co., Inc. Substituted pyridyl pyrroles, compositions containing such compounds and methods of use
AR008789A1 (es) * 1996-07-31 2000-02-23 Bayer Corp Piridinas y bifenilos substituidos
US5776954A (en) * 1996-10-30 1998-07-07 Merck & Co., Inc. Substituted pyridyl pyrroles, compositions containing such compounds and methods of use
WO1998021957A1 (en) 1996-11-20 1998-05-28 Merck & Co., Inc. Triaryl substituted imidazoles, compositions containing such compounds and methods of use
EP0959886A4 (en) 1996-11-20 2001-05-02 Merck & Co Inc TRIARYL SUBSTITUTED IMIDAZOLES AS GLUCAGON ANTAGONISTS
EP0959885A4 (en) 1996-11-20 2002-07-17 Merck & Co Inc TRIARYL SUBSTITUTED IMIDAZOLES AND METHODS OF USE
DE69719544T2 (de) * 1996-12-12 2003-11-06 Banyu Pharmaceutical Co., Ltd. Pyrazolderivate
EE200300169A (et) 1997-04-18 2003-06-16 G.D. Searle & Co. Tsüklooksügenaas-2 inhibiitorite kasutamise meetod südame-veresoonkonna haiguste ärahoidmiseks
US6613942B1 (en) * 1997-07-01 2003-09-02 Novo Nordisk A/S Glucagon antagonists/inverse agonists
EP1024134A4 (en) * 1997-10-09 2003-05-14 Ono Pharmaceutical Co DERIVATIVES OF AMINOBUTANIC ACID
IL136711A0 (en) 1997-12-19 2001-06-14 Amgen Inc Substituted pyridine and pyridazine compounds and their pharmaceutical use
GEP20033045B (en) 1998-09-17 2003-08-25 Bristol Myers Squibb Co Method for Treating Diabetes
US6503949B1 (en) * 1999-05-17 2003-01-07 Noro Nordisk A/S Glucagon antagonists/inverse agonists
JP2003506443A (ja) * 1999-08-10 2003-02-18 バイエルクロップサイエンス株式会社 除草性テトラゾリノン誘導体
IL149493A0 (en) * 1999-11-10 2002-11-10 Takeda Chemical Industries Ltd 5-membered n-heterocyclic compounds with hypoglycemic and hypolipidemic activity
US6562807B2 (en) * 2000-06-23 2003-05-13 Novo Nordisk A/S Glucagon antagonists/inverse agonists
AU7705601A (en) * 2000-07-25 2002-02-05 Merck & Co Inc N-substituted indoles useful in the treatment of diabetes
AU2002223501A1 (en) 2000-11-17 2002-05-27 Agouron Pharmaceuticals, Inc. Glucagon antagonists/inverse agonists
US20030203946A1 (en) 2000-11-17 2003-10-30 Carsten Behrens Glucagon antagonists/inverse agonists
ITMI20010733A1 (it) * 2001-04-05 2002-10-05 Recordati Chem Pharm Uso di inibitori dell'isoenzina cox-2 per il trattamento dell'incontinenza urinaria
US6762318B2 (en) * 2001-12-03 2004-07-13 Novo Nordisk A/S Glucagon antagonists
US6881746B2 (en) * 2001-12-03 2005-04-19 Novo Nordick A/S Glucagon antagonists/inverse agonists
AU2002351730A1 (en) 2001-12-19 2003-06-30 Novo Nordisk A/S Glucagon receptor antagonists/inverse agonists
AU2002347022A1 (en) 2001-12-20 2003-07-09 Novo Nordisk A/S Benzimidazols and indols as glucagon receptor antagonists/inverse agonisten
WO2003064404A1 (en) * 2002-02-01 2003-08-07 Dainippon Pharmaceutical Co., Ltd. 2-furancarboxylic acid hydrazides and pharmaceutical compositions containing the same
ATE505223T1 (de) 2002-07-19 2011-04-15 Baxter Int System für die peritonealdialyse
EP1400243A1 (en) 2002-09-19 2004-03-24 Tanabe Seiyaku Co., Ltd. Calcium-activated K channel activator
CA2508581A1 (en) * 2002-12-04 2004-06-17 Merck & Co., Inc. Spirocyclic ureas, compositions containing such compounds and methods of use
AU2004210127B2 (en) * 2003-01-27 2009-10-01 Merck Sharp & Dohme Corp. Substituted pyrazoles, compositions containing such compounds and methods of use
EA200501607A1 (ru) * 2003-04-14 2006-06-30 ДЗЕ ИНСТИТЬЮТС ФОР ФАРМАСЬЮТИКАЛ ДИСКАВЕРИ, ЭлЭлСи Замещённые фенилалкановые кислоты
CA2524436A1 (en) * 2003-05-09 2004-11-25 Merck & Co., Inc. Benzimidazoles, compositions containing such compounds and methods of use
NZ551405A (en) 2004-06-04 2009-06-26 Merck & Co Inc Pyrazole derivatives, compositions containing such compounds and methods of use
WO2006014618A2 (en) * 2004-07-22 2006-02-09 Merck & Co., Inc. Substituted pyrazoles, compositions containing such compounds and methods of use
AR056574A1 (es) * 2005-10-19 2007-10-10 Merck & Co Inc Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso

Also Published As

Publication number Publication date
EP1756064A2 (en) 2007-02-28
ATE395338T1 (de) 2008-05-15
AU2008229701C1 (en) 2010-07-29
CY1108544T1 (el) 2014-04-09
NO339149B1 (no) 2016-11-14
NZ551405A (en) 2009-06-26
AU2008229701A1 (en) 2008-10-30
UA85884C2 (uk) 2009-03-10
JP2008505062A (ja) 2008-02-21
EP1756064B1 (en) 2008-05-14
IL179754A (en) 2013-12-31
DK1756064T3 (da) 2008-09-22
JP4733153B2 (ja) 2011-07-27
EA012431B1 (ru) 2009-10-30
JP4108739B2 (ja) 2008-06-25
MXPA06014084A (es) 2007-02-15
NI200600290A (es) 2007-08-07
WO2005121097A3 (en) 2006-02-16
BRPI0511703B8 (pt) 2021-05-25
CN1964947A (zh) 2007-05-16
AR088919A2 (es) 2014-07-16
CA2566945C (en) 2010-09-21
CA2566945A1 (en) 2005-12-22
TNSN06397A1 (en) 2008-02-22
PL1756064T3 (pl) 2008-11-28
PT1756064E (pt) 2008-07-22
AU2005252183A1 (en) 2005-12-22
BRPI0511703A (pt) 2008-01-08
TWI293952B (en) 2008-03-01
PE20060427A1 (es) 2006-06-19
US20090176854A1 (en) 2009-07-09
DE602005006806D1 (de) 2008-06-26
EA200602196A1 (ru) 2007-06-29
MA28673B1 (fr) 2007-06-01
CR8766A (es) 2007-08-28
US20050272794A1 (en) 2005-12-08
US7598285B2 (en) 2009-10-06
TW200604179A (en) 2006-02-01
US7799818B2 (en) 2010-09-21
ES2306165T3 (es) 2008-11-01
AU2008229701B2 (en) 2010-03-04
GEP20094605B (en) 2009-02-10
AU2005252183B2 (en) 2008-07-17
NO20070073L (no) 2007-03-05
JP2008150388A (ja) 2008-07-03
HRP20080311T3 (hr) 2008-07-31
MY143599A (en) 2011-06-15
BRPI0511703B1 (pt) 2018-07-17
IL179754A0 (en) 2007-05-15
ZA200609489B (en) 2007-10-31
WO2005121097A2 (en) 2005-12-22
AR049291A1 (es) 2006-07-12
SI1756064T1 (sl) 2008-12-31

Similar Documents

Publication Publication Date Title
ECSP067062A (es) Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso
CR10694A (es) Compuestos antagonistas del receptor de glucagon, composiciones que contienen dichos compuestos y procedimientos de uso
CY1109916T1 (el) Βενζιμιδαζολο-θειοφαινικες ενωσεις ως plk αναστολεις
UY28342A1 (es) Nuevos compuestos
PA8720801A1 (es) Nuevas combinaciones terapeuticas para el tratamiento de la depresion
UY29781A1 (es) Compuestos diazaspiro sustituidos, sales farmacéuticamente aceptables, composiciones farmacéuticas que contienen los compuestos o sales, métodos de preparación y usos
UY28941A1 (es) Indazoles sustituidos, composiciones que los contienen, procedimiento de preparacion y su uso
CL2004001069A1 (es) Compuestos derivados de 1-benzoil-isoquinolinas sustituidos; procedimiento de preparacion, composicion farmaceutica; y uso para el tratamiento o profilaxis de diabetes tipo ii.
ECSP034774A (es) Pirazolopirimmidinas como agentes terapeuticos
ECSP034773A (es) Pirazolopirimmidinas como agentes terapeuticos
HN2002000275A (es) Derivados de 1,8 naftiridina y su uso para el tratamiento de diabetes y trastornos relacionados
UY28348A1 (es) Compuestos novedosos
UY29087A1 (es) Derivados de adamantilo, composiciones farmaceuticas que los contienen, procesos para su preparacion y uso terapeutico
GT200500307A (es) Compuestos quimicos
ECSP105253A (es) Derivados de 5-feniltiazol y uso como inhibidores de pi3 cinasa
UY29796A1 (es) Nuevos compuestos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor
DK1934174T3 (da) Azetidiner som MEK inhibitorer til behandling af proliferative sygdomme
ECSP088246A (es) Nuevos derivados de benzotiazolona
ITMI20031570A1 (it) Composizione per uso dietetico, farmaceutico o cosmetico
UY30736A1 (es) Compuestos quimicos 537
CL2008000202A1 (es) Compuestos derivados de n-aril-acetamida, antagonista trpv1;composicion farmaceutica que los comprende, utiles en el tratamiento del dolor.
GT200600163A (es) Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de la depresion
DOP2006000231A (es) Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso
ECSP088366A (es) 1,2-diarilimidazoles para uso como moduladores de cb1
DOP2006000268A (es) Agentes antibacterianos